Claudia Lewis, partner with Venable LLP, describes how the U.S. Food and Drug Administration is revising its policies, practices and regulations in response to the coronavirus pandemic.
Vito Calabretta, senior vice president of global operations with Tecsys, relates how supply chains are adjusting to the coronavirus pandemic, and how they might be permanently changed when it's over.
Christopher Tang, professor at UCLA's Anderson School of Management, describes what it will take for hospital and healthcare supply chains to recover from the COVID-19 pandemic.
Mike Piccarreta, partner with Kearney, speaks about the ability of the healthcare system’s supply chain to react to national emergencies, and the vulnerabilities that have been exposed as a result of the coronavirus pandemic.
The Trump administration plans to pump millions of dollars into producing more medications in the U.S. as the coronavirus pandemic heightens longstanding concerns about the fragility of the global drug supply chain.
The coronavirus pandemic has affected virtually every country in the world, but the ability to combat it with essential medicines varies widely. Low- and middle-income countries (LMICs) are finding it especially tough to access medicines, and ensure the safety and quality of those products that are available.